Bifidobacterium adolescentis, a prominent species in the human gut microbiome, demonstrates extensive health benefits in research studies.
Emerging research highlights its role in modulating inflammation, supporting metabolic health, and enhancing immune function.
Notably, B. adolescentis shows promise in preventing and treating various conditions, such as necrotizing enterocolitis in neonates, non-alcoholic fatty liver disease, and rheumatoid arthritis.
Early administration of B. adolescentis has been particularly effective in balancing gut microbiota, reducing pro-inflammatory responses, and promoting overall gut health.
Its ability to produce short-chain fatty acids and synthesize B vitamins further underscores its potential as a therapeutic agent.
Increasingly, the benefits of Bifidobacteria for gut and overall health are demonstrated in research. While specific strains are mentioned here, many of these benefits are widely attributed to Bifidobacteria as a genus.
These benefits include preventing diarrhea, improving lactose intolerance, and enhancing immune modulation. [31.]
They are effective in promoting colon regularity and alleviating constipation, while also preventing oral inflammations and dental caries. [5., 24.]
Bifidobacteria compete with pathogens, protecting against infections and inhibiting virus replication, such as Coxsackievirus B3 and rotavirus. [3., 5., 7., 8., 31.]
They show anticancer properties by enhancing immune response, inhibiting cancer cell growth, and altering gut conditions to prevent tumors. [5.]
Additionally, Bifidobacteria boost immune responses, increase beneficial antibodies, and promote regulatory T cells, contributing to anti-inflammatory effects and immune balance. [5., 12.]
They also act as psychobiotics, reducing stress, anxiety, and depression, and play a role in synthesizing gamma-Aminobutyric acid (GABA), which is particularly beneficial for individuals with autism. [2., 5., 9., 16., 24., 33., 34., 36.]
Moreover, Bifidobacteria facilitate the absorption of vitamins and minerals, promote bone density and repair, and enhance metabolic health by reducing fat accumulation and improving glucose tolerance. [1., 4., 5., 19., 25., 27., 31., 32.]
Bifidobacterium adolescentis displays distinct anti-inflammatory properties, which can help reduce inflammation in the gut and other parts of the body. [6.]
B. adolescentis exhibits antioxidant properties, which can help protect cells from oxidative stress and damage. It may also mitigate damage from hypoxic conditions in the brain. [18.]
B. adolescentis IM38 has also been shown to inhibit NF-κB activation. [5.]
Studies indicate that B. adolescentis can alleviate anxiety and depression-like phenotypes, possibly by modulating the gut microbiota-inflammation axis.
This bacterium contributes to the production of gamma-aminobutyric acid (GABA), a neurotransmitter that helps reduce stress and anxiety.
Strains of B. adolescentis have also been shown to regulate gut immune responses and microbiota composition, and to modulate the benzodiazepine site of the GABAA receptor and stress-related cytokine expression.
B. adolescentis efficiently ferments prebiotic carbohydrates, which supports gut health. [20.]
B. adolescentis also produces beneficial short-chain fatty acids (SCFAs) such as acetate and lactate through the ‘bifid shunt’ pathway, enhancing energy metabolism. [20.]
B. adolescentis produces acetic acid and lactic acid, which are associated with various health benefits including improved gut barrier function and reduced inflammation. [20.]
Probiotic bacteria, especially Bifidobacterium strains like B. adolescentis, have been extensively studied for their ability to produce folate, an essential B vitamin.
Unlike many lactobacilli, which generally cannot synthesize folate, several strains of Bifidobacterium, including B. adolescentis, can produce and release significant amounts of this vitamin, which they do via the para-aminobenzoic acid (pABA) pathway for folate production. [29.]
B. adolescentis can strengthen the intestinal barrier, preventing pathogenic bacteria and toxins from entering the body. [18.]
Certain strains of B. adolescentis possess antiviral properties, which can help protect against viral infections including coxsackie virus. [17.]
Bifidobacterium adolescentis has gained attention as a potential probiotic supplement due to its numerous health benefits and natural presence in the human gut microbiome.
Bifidobacterium adolescentis is a dominant species in the human large intestine, particularly in adults. [20.] It has been shown to provide benefit in various health conditions.
Metabolic and Obesity-Related Benefits [6.]
One study of high-fat (HF) diet-fed rats revealed that B. adolescentis supplementation significantly reduced body weight, fat pad weight, and liver steatosis in these rats. Additionally, it improved insulin sensitivity.
Overall, B. adolescentis shows potential as a beneficial supplement to counteract obesity-related metabolic disturbances, suggesting a role in managing conditions like metabolic syndrome.
NAFLD (Nonalcoholic Fatty Liver Disease) and Steatohepatitis [21.]
Bifidobacterium adolescentis, a common gut bacterium, has been found to alleviate non-alcoholic fatty liver disease (NAFLD) and steatohepatitis.
In a study involving male C57BL/6J mice on a choline-deficient high-fat diet, supplementation with B. adolescentis significantly reduced liver steatosis and inflammation. This improvement was linked to preserving the gut barrier, reducing gut-derived lipopolysaccharide (LPS), and inhibiting the hepatic TLR4/NF-κB pathway.
Overall, B. adolescentis shows promise as a potential treatment for NAFLD by modulating gut microbiota interactions and improving FGF21 signaling.
Rheumatoid Arthritis [11.]
Recent studies have explored the role of probiotics in modulating inflammation by altering gut microbiota, which is recognized as a critical factor in the development of rheumatoid arthritis (RA).
Dysbiosis, or imbalance in gut microbiota, often occurs before clinical symptoms of arthritis. One study compared the effects of preventive versus therapeutic treatment with Bifidobacterium adolescentis on collagen-induced arthritis (CIA) in rats. [11.]
Its results suggest that early intervention with B. adolescentis may be effective in alleviating rheumatoid arthritis by preventing dysbiosis and modulating inflammatory responses. [11.
Coxsackie Virus Infections [17.]
One study explored the antiviral properties of B. adolescentis SPM1605 against Coxsackievirus B3 (CVB3).
Among 13 isolates, B. adolescentis SPM1605 exhibited the most significant antiviral activity, reducing the viral RNA levels by 50% in infected cells. This strain demonstrated strain-specific antiviral effects, suggesting that B. adolescentis SPM1605 could be a promising alternative therapy for CVB3 infections.
Necrotizing Enterocolitis in Neonates [36.]
Bifidobacterium adolescentis has been shown to protect premature neonatal rats against necrotizing enterocolitis (NEC), a severe gastrointestinal disorder.
In a study, neonatal rats fed with B. adolescentis had a significantly higher survival rate and reduced incidence of NEC-like intestinal injury compared to those not given the probiotic. [36.]
Other types of bifidobacteria have also been associated with lower incidences of necrotizing enterocolitis, especially in neonates born before 34 weeks gestation. [26.]
Bifidobacterium adolescentis supplements are typically available in various forms to cater to different consumer preferences and needs.
These may include capsules, powders, and liquid formulations. Some supplements contain Bifidobacterium adolescentis as a single strain, while others combine it with other probiotic species or prebiotic fibers to enhance its effectiveness.
While Bifidobacterium adolescentis is generally considered safe due to its natural presence in the human gut, it's important to note that the safety and efficacy of probiotic supplements can vary depending on the specific strain and formulation.
Regulatory standards for probiotic supplements differ across countries, and consumers should look for products that have undergone rigorous quality control and safety testing.
It's advisable to consult with a healthcare professional before starting any new supplement regimen, especially for individuals with underlying health conditions or compromised immune systems.
Bifidobacteria levels are assessed in stool samples. Stool samples may be collected from the comfort of home.
Testing may require avoidance of certain medications and/or supplements including probiotics prior to sample collection. It is important to consult with the ordering provider for full test preparation instructions.
It is important to consult with the laboratory company used for test interpretation.
B. adolescentis levels are often reported as part of the total Bifidobacteria spp. present.
One lab company provides the following reference range for Bifidobacteria spp. levels: 6.7e7org/g [26.]
High levels of Bifidobacteria in the gut microbiome are generally associated with a healthy state and favorable metabolic outcomes.
In the setting of symptoms of dysbiosis or SIBO such as gas, bloating, and/or abdominal pain, further assessment and possible treatments should be considered.
Patients in this scenario who are using probiotics should consider stopping their probiotics.
In rare clinical settings involving either the very young or the very elderly who also have impaired intestinal barriers and/or are immunocompromised, Bifidobacteria may become invasive and cause bacteremia. [10.]
Generally, Bifidobacteria are considered to be beneficial. Low levels of Bifidobacteria have been associated with:
Therefore, maintaining a high abundance of Bifidobacteria spp. in the gut microbiome is generally considered a favorable state, associated with better metabolic health, a lean phenotype, and a lower risk of inflammatory conditions like IBD.
Monitoring Bifidobacteria levels may have clinical significance in assessing gut health, disease risk, and potential therapeutic interventions aimed at restoring a balanced microbiome.
A healthy diet and lifestyle are foundational for microbiome health.
Click here to compare testing options and order tests to assess Bifidobacteria levels.
[1.] Al-Sheraji S. H., Ismail A., Manap M. Y., Mustafa S., Yusof R. M., Hassan F. A. (2012). Hypocholesterolaemic Effect of Yoghurt Containing Bifidobacterium Pseudocatenulatum G4 or Bifidobacterium Longum BB536. Food Chem. 135, 356–361. 10.1016/j.foodchem.2012.04.120
[2.] Allen A. P., Hutch W., Borre Y. E., Kennedy P. J., Temko A., Boylan G., et al. (2016). Bifidobacterium Longum 1714 as a Translational Psychobiotic: Modulation of Stress, Electrophysiology and Neurocognition in Healthy Volunteers. Transl Psychiatry 6, e939. 10.1038/tp.2016.191
[3.] Bae E.-A., Han M. J., Song M.-J., Kim D.-H. (2002). Purification of Rotavirus Infection-Inhibitory Protein from Bifidobacterium Breve K-110. Seoul: COREE, REPUBLIQUE DE, Korean Society for Applied Microbiology.
[4.] Ballini A, Gnoni A, De Vito D, et al. Effect of probiotics on the occurrence of nutrition absorption capacities in healthy children: a randomized double-blinded placebo-controlled pilot study. European Review for Medical and Pharmacological Sciences. 2019;23(19):8645-8657. doi:https://doi.org/10.26355/eurrev_201910_19182
[5.] Chen J, Chen X, Ho CL. Recent Development of Probiotic Bifidobacteria for Treating Human Diseases. Front Bioeng Biotechnol. 2021 Dec 22;9:770248. doi: 10.3389/fbioe.2021.770248. PMID: 35004640; PMCID: PMC8727868.
[6.] Chen J, Wang R, Li XF, Wang RL. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr. 2012 May;107(10):1429-34. doi: 10.1017/S0007114511004491. Epub 2011 Sep 14. PMID: 21914236.
[7.] Chenoll E, Rivero M, Codoñer FM, Martinez-Blanch JF, Ramón D, Genovés S, Moreno Muñoz JA. Complete Genome Sequence of Bifidobacterium longum subsp. infantis Strain CECT 7210, a Probiotic Strain Active against Rotavirus Infections. Genome Announc. 2015 Apr 2;3(2):e00105-15. doi: 10.1128/genomeA.00105-15. PMID: 25838473; PMCID: PMC4384477.
[8.] Corrêa NB, Péret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005 May-Jun;39(5):385-9. doi: 10.1097/01.mcg.0000159217.47419.5b. PMID: 15815206.
[9.] Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013 Nov 15;74(10):720-6. doi: 10.1016/j.biopsych.2013.05.001. Epub 2013 Jun 10. PMID: 23759244.
[10.] Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium Bacteremia: Clinical Characteristics and a Genomic Approach To Assess Pathogenicity. J Clin Microbiol. 2017 Jul;55(7):2234-2248. doi: 10.1128/JCM.00150-17. Epub 2017 May 10. PMID: 28490487; PMCID: PMC5483926.
[11.] Fan Z , Yang B , Ross RP , Stanton C , Shi G , Zhao J , Zhang H , Chen W . Protective effects of Bifidobacterium adolescentis on collagen-induced arthritis in rats depend on timing of administration. Food Funct. 2020 May 1;11(5):4499-4511. doi: 10.1039/d0fo00077a. Epub 2020 May 8. PMID: 32383727.
[12.] Fukushima Y, Kawata Y, Mizumachi K, Kurisaki J, Mitsuoka T. Effect of bifidobacteria feeding on fecal flora and production of immunoglobulins in lactating mouse. Int J Food Microbiol. 1999 Feb 18;46(3):193-7. doi: 10.1016/s0168-1605(98)00183-4. PMID: 10100899.
[13.] Hidalgo-Cantabrana C, et al. Bifidobacteria and Their Health-Promoting Effects. Bugs as Drugs. Published online February 1, 2018:73-98. doi:https://doi.org/10.1128/microbiolspec.bad-0010-2016
[14.] Hou, K., Wu, ZX., Chen, XY. et al. Microbiota in health and diseases. Sig Transduct Target Ther 7, 135 (2022). https://doi.org/10.1038/s41392-022-00974-4
[15.] Jang H. M., Jang S.-E., Han M. J., Kim D.-H. (2018). Anxiolytic-like Effect of Bifidobacterium Adolescentis IM38 in Mice with or without Immobilisation Stress. Beneficial microbes 9, 123–132. 10.3920/bm2016.0226
[16.] Jang H.-M., Lee K.-E., Kim D.-H. (2019). The Preventive and Curative Effects of Lactobacillus Reuteri NK33 and Bifidobacterium Adolescentis NK98 on Immobilization Stress-Induced Anxiety/depression and Colitis in Mice. Nutrients 11, 819. 10.3390/nu11040819
[17.] Kim MJ, Lee DK, Park JE, Park IH, Seo JG, Ha NJ. Antiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3. Biotechnology, Biotechnological Equipment. 2014;28(4):681-688. doi:https://doi.org/10.1080/13102818.2014.945237
[18.] Krumbeck JA, Rasmussen HE, Hutkins RW, Clarke J, Shawron K, Keshavarzian A, Walter J. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018 Jun 28;6(1):121. doi: 10.1186/s40168-018-0494-4. PMID: 29954454; PMCID: PMC6022452.
[19.] Leahy SC, Higgins DG, Fitzgerald GF, van Sinderen D. Getting better with bifidobacteria. J Appl Microbiol. 2005;98(6):1303-15. doi: 10.1111/j.1365-2672.2005.02600.x. PMID: 15916644.
[20.] Leser T, Baker A. Bifidobacterium adolescentis - a beneficial microbe. Beneficial Microbes. 2023;14(6):525-551. doi:https://doi.org/10.1163/18762891-20230030
[21.] Long X, Liu D, Gao Q, Ni J, Qian L, Ni Y, Fang Q, Jia W, Li H. Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity. Front Endocrinol (Lausanne). 2021 Dec 30;12:773340. doi: 10.3389/fendo.2021.773340. PMID: 35035378; PMCID: PMC8756294.
[22.] Mehra A, Arora G, Sahni G, et al. Gut microbiota and Autism Spectrum Disorder: From pathogenesis to potential therapeutic perspectives. Journal of Traditional and Complementary Medicine. 2022;13(2). doi:https://doi.org/10.1016/j.jtcme.2022.03.001
[23.] Milani C, Turroni F, Duranti S, Lugli GA, Mancabelli L, Ferrario C, van Sinderen D, Ventura M. Genomics of the Genus Bifidobacterium Reveals Species-Specific Adaptation to the Glycan-Rich Gut Environment. Appl Environ Microbiol. 2015 Nov 20;82(4):980-991. doi: 10.1128/AEM.03500-15. PMID: 26590291; PMCID: PMC4751850.
[24.] O'Callaghan A, van Sinderen D. Bifidobacteria and Their Role as Members of the Human Gut Microbiota. Front Microbiol. 2016 Jun 15;7:925. doi: 10.3389/fmicb.2016.00925. PMID: 27379055; PMCID: PMC4908950.
[25.] Parvaneh K, Ebrahimi M, Sabran MR, Karimi G, Hwei AN, Abdul-Majeed S, Ahmad Z, Ibrahim Z, Jamaluddin R. Probiotics (Bifidobacterium longum) Increase Bone Mass Density and Upregulate Sparc and Bmp-2 Genes in Rats with Bone Loss Resulting from Ovariectomy. Biomed Res Int. 2015;2015:897639. doi: 10.1155/2015/897639. Epub 2015 Aug 20. PMID: 26366421; PMCID: PMC4558422.
[26.] Patole SK, Rao SC, Keil AD, Nathan EA, Doherty DA, Simmer KN. Benefits of Bifidobacterium breve M-16V Supplementation in Preterm Neonates - A Retrospective Cohort Study. PLoS One. 2016 Mar 8;11(3):e0150775. doi: 10.1371/journal.pone.0150775. PMID: 26953798; PMCID: PMC4783036.
[27.] Pedret A, Valls RM, Calderón-Pérez L, Llauradó E, Companys J, Pla-Pagà L, Moragas A, Martín-Luján F, Ortega Y, Giralt M, Caimari A, Chenoll E, Genovés S, Martorell P, Codoñer FM, Ramón D, Arola L, Solà R. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019 Sep;43(9):1863-1868. doi: 10.1038/s41366-018-0220-0. Epub 2018 Sep 27. PMID: 30262813; PMCID: PMC6760601.
[28.] Pinto-Sanchez M. I., Hall G. B., Ghajar K., Nardelli A., Bolino C., Lau J. T., et al. (2017). Probiotic Bifidobacterium Longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients with Irritable Bowel Syndrome. Gastroenterology 153, 448–459. e8. 10.1053/j.gastro.2017.05.003
[29.] Rossi M, Amaretti A, Raimondi S. Folate production by probiotic bacteria. Nutrients. 2011 Jan;3(1):118-34. doi: 10.3390/nu3010118. Epub 2011 Jan 18. PMID: 22254078; PMCID: PMC3257725.
[30.] Rupa Health. GI-MAP + Zonulin Sample Report.pdf. Google Docs. https://drive.google.com/file/d/13LXmPBhXV2Y9paOeE5id2OM2X0V5gJ56/view
[31.] Schell MA, Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G, Zwahlen MC, Desiere F, Bork P, Delley M, Pridmore RD, Arigoni F. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14422-7. doi: 10.1073/pnas.212527599. Epub 2002 Oct 15. Erratum in: Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9430. PMID: 12381787; PMCID: PMC137899.
[32.] Stenman LK, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes. 2014 Dec;5(4):437-45. doi: 10.3920/BM2014.0014. PMID: 25062610.
[33.] Tian P., Bastiaanssen T. F. S., Song L., Jiang B., Zhang X., Zhao J., et al. (2021). Unraveling the Microbial Mechanisms Underlying the Psychobiotic Potential of a Bifidobacterium Breve Strain. Mol. Nutr. Food Res. 65, 2000704. 10.1002/mnfr.202000704
[34.] Tian P., O'Riordan K. J., Lee Y.-K., Wang G., Zhao J., Zhang H., et al. (2020). Towards a Psychobiotic Therapy for Depression: Bifidobacterium Breve CCFM1025 Reverses Chronic Stress-Induced Depressive Symptoms and Gut Microbial Abnormalities in Mice. Neurobiol. Stress 12, 100216. 10.1016/j.ynstr.2020.100216
[35.] Wang H., Braun C., Murphy E. F., Enck P. (2019). Bifidobacterium Longum 1714 Strain Modulates Brain Activity of Healthy Volunteers during Social Stress. Am. J. Gastroenterol. 114, 1152–1162. 10.14309/ajg.0000000000000203
[36.] Wu W, Wang Y, Zou J, Long F, Yan H, Zeng L, Chen Y. Bifidobacterium adolescentis protects against necrotizing enterocolitis and upregulates TOLLIP and SIGIRR in premature neonatal rats. BMC Pediatr. 2017 Jan 5;17(1):1. doi: 10.1186/s12887-016-0759-7. PMID: 28056921; PMCID: PMC5217633.